Prospect Financial Group LLC Buys Shares of 13,809 Haleon plc (NYSE:HLN)

Prospect Financial Group LLC purchased a new stake in Haleon plc (NYSE:HLN) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 13,809 shares of the company’s stock, valued at approximately $132,000.

A number of other institutional investors also recently modified their holdings of the business. FMR LLC grew its position in Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after acquiring an additional 5,768,117 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Haleon by 49.9% in the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock valued at $96,833,000 after purchasing an additional 3,046,841 shares in the last quarter. Douglas Lane & Associates LLC grew its holdings in shares of Haleon by 1.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock valued at $82,274,000 after purchasing an additional 161,865 shares during the last quarter. JPMorgan Chase & Co. increased its position in Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Haleon in the 4th quarter valued at approximately $42,193,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Down 1.4 %

Shares of HLN stock opened at $10.13 on Tuesday. Haleon plc has a 1-year low of $7.99 and a 1-year high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a market cap of $45.88 billion, a price-to-earnings ratio of 29.81, a PEG ratio of 2.82 and a beta of 0.25. The stock has a 50-day moving average of $9.87 and a 200-day moving average of $9.88.

Haleon (NYSE:HLN) last announced its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. On average, equities research analysts forecast that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The company also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio is 58.97%.

Analysts Set New Price Targets

A number of analysts have weighed in on HLN shares. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. HSBC reiterated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Six investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.